BIOTE CORP -A (BTMD) Stock Fundamental Analysis
USA - NASDAQ:BTMD - US0906831039 - Common Stock
3.37 USD
+0.04 (+1.2%)
3.37 USD
0 (0%)
Overall BTMD gets a fundamental rating of 5 out of 10. We evaluated BTMD against 196 industry peers in the Pharmaceuticals industry. BTMD has an average financial health and profitability rating. BTMD may be a bit undervalued, certainly considering the very reasonable score on growth
1. Profitability
1.1 Basic Checks
BTMD had positive earnings in the past year.
BTMD had a positive operating cash flow in the past year.
Of the past 5 years BTMD 4 years were profitable.
BTMD had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of 29.87%, BTMD belongs to the top of the industry, outperforming 98.47% of the companies in the same industry.
Looking at the Return On Invested Capital, with a value of 51.55%, BTMD belongs to the top of the industry, outperforming 99.49% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 29.87% | ||
| ROE | N/A | ||
| ROIC | 51.55% |
ROA(3y)1.27%
ROA(5y)30.69%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With an excellent Profit Margin value of 15.73%, BTMD belongs to the best of the industry, outperforming 89.80% of the companies in the same industry.
BTMD's Profit Margin has declined in the last couple of years.
With an excellent Operating Margin value of 17.79%, BTMD belongs to the best of the industry, outperforming 86.73% of the companies in the same industry.
In the last couple of years the Operating Margin of BTMD has declined.
The Gross Margin of BTMD (71.89%) is better than 80.10% of its industry peers.
BTMD's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 17.79% | ||
| PM (TTM) | 15.73% | ||
| GM | 71.89% |
OM growth 3Y-13.56%
OM growth 5Y-5.58%
PM growth 3Y-59.09%
PM growth 5Y-39.26%
GM growth 3Y2.76%
GM growth 5Y3.16%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so BTMD is creating value.
Compared to 1 year ago, BTMD has less shares outstanding
The debt/assets ratio for BTMD is higher compared to a year ago.
2.2 Solvency
BTMD has an Altman-Z score of 2.46. This is not the best score and indicates that BTMD is in the grey zone with still only limited risk for bankruptcy at the moment.
BTMD has a Altman-Z score of 2.46. This is in the better half of the industry: BTMD outperforms 69.39% of its industry peers.
The Debt to FCF ratio of BTMD is 4.35, which is a neutral value as it means it would take BTMD, 4.35 years of fcf income to pay off all of its debts.
BTMD has a better Debt to FCF ratio (4.35) than 84.69% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 4.35 | ||
| Altman-Z | 2.46 |
ROIC/WACC5.27
WACC9.78%
2.3 Liquidity
A Current Ratio of 0.98 indicates that BTMD may have some problems paying its short term obligations.
BTMD has a Current ratio of 0.98. This is amonst the worse of the industry: BTMD underperforms 82.14% of its industry peers.
BTMD has a Quick Ratio of 0.98. This is a bad value and indicates that BTMD is not financially healthy enough and could expect problems in meeting its short term obligations.
BTMD has a Quick ratio of 0.74. This is amonst the worse of the industry: BTMD underperforms 83.67% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.98 | ||
| Quick Ratio | 0.74 |
3. Growth
3.1 Past
BTMD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 366.67%, which is quite impressive.
The earnings per share for BTMD have been decreasing by -48.53% on average. This is quite bad
The Revenue for BTMD has decreased by -14.94% in the past year. This is quite bad
Measured over the past years, BTMD shows a quite strong growth in Revenue. The Revenue has been growing by 12.38% on average per year.
EPS 1Y (TTM)366.67%
EPS 3Y-71.33%
EPS 5Y-48.53%
EPS Q2Q%220%
Revenue 1Y (TTM)-14.94%
Revenue growth 3Y12.26%
Revenue growth 5Y12.38%
Sales Q2Q%-0.62%
3.2 Future
Based on estimates for the next years, BTMD will show a very strong growth in Earnings Per Share. The EPS will grow by 42.78% on average per year.
The Revenue is expected to grow by 6.82% on average over the next years.
EPS Next Y166.59%
EPS Next 2Y40.1%
EPS Next 3Y24.88%
EPS Next 5Y42.78%
Revenue Next Year-2.93%
Revenue Next 2Y0.89%
Revenue Next 3Y2.93%
Revenue Next 5Y6.82%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
BTMD is valuated cheaply with a Price/Earnings ratio of 3.44.
97.45% of the companies in the same industry are more expensive than BTMD, based on the Price/Earnings ratio.
BTMD is valuated cheaply when we compare the Price/Earnings ratio to 27.20, which is the current average of the S&P500 Index.
Based on the Price/Forward Earnings ratio of 7.80, the valuation of BTMD can be described as very cheap.
Based on the Price/Forward Earnings ratio, BTMD is valued cheaply inside the industry as 91.33% of the companies are valued more expensively.
BTMD's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 22.70.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 3.44 | ||
| Fwd PE | 7.8 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, BTMD is valued cheaper than 92.35% of the companies in the same industry.
BTMD's Price/Free Cash Flow ratio is rather cheap when compared to the industry. BTMD is cheaper than 97.96% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 4.81 | ||
| EV/EBITDA | 7.55 |
4.3 Compensation for Growth
BTMD's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
BTMD has a very decent profitability rating, which may justify a higher PE ratio.
BTMD's earnings are expected to grow with 24.88% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.02
PEG (5Y)N/A
EPS Next 2Y40.1%
EPS Next 3Y24.88%
5. Dividend
5.1 Amount
BTMD does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
3.37
+0.04 (+1.2%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners66.02%
Inst Owner Change-1.76%
Ins Owners9.81%
Ins Owner Change8.21%
Market Cap166.61M
Analysts81.67
Price Target5.51 (63.5%)
Short Float %2.72%
Short Ratio4.98
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)318.36%
Min EPS beat(2)178.65%
Max EPS beat(2)458.07%
EPS beat(4)3
Avg EPS beat(4)223.56%
Min EPS beat(4)-1.96%
Max EPS beat(4)458.07%
EPS beat(8)5
Avg EPS beat(8)86.5%
EPS beat(12)6
Avg EPS beat(12)-127.37%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-0.83%
Min Revenue beat(2)-3.31%
Max Revenue beat(2)1.66%
Revenue beat(4)1
Avg Revenue beat(4)-2.07%
Min Revenue beat(4)-4.66%
Max Revenue beat(4)1.66%
Revenue beat(8)2
Avg Revenue beat(8)-2.3%
Revenue beat(12)4
Avg Revenue beat(12)-1.33%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-18.93%
PT rev (3m)-18.93%
EPS NQ rev (1m)-33.33%
EPS NQ rev (3m)-54.83%
EPS NY rev (1m)-5.74%
EPS NY rev (3m)-1.43%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-8.91%
Revenue NY rev (1m)-5.86%
Revenue NY rev (3m)-5.86%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 3.44 | ||
| Fwd PE | 7.8 | ||
| P/S | 0.84 | ||
| P/FCF | 4.81 | ||
| P/OCF | 4.02 | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | 7.55 |
EPS(TTM)0.98
EY29.08%
EPS(NY)0.43
Fwd EY12.81%
FCF(TTM)0.7
FCFY20.77%
OCF(TTM)0.84
OCFY24.89%
SpS4.03
BVpS-1.72
TBVpS-2.01
PEG (NY)0.02
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 29.87% | ||
| ROE | N/A | ||
| ROCE | 65.25% | ||
| ROIC | 51.55% | ||
| ROICexc | 80.7% | ||
| ROICexgc | 137.37% | ||
| OM | 17.79% | ||
| PM (TTM) | 15.73% | ||
| GM | 71.89% | ||
| FCFM | 17.39% |
ROA(3y)1.27%
ROA(5y)30.69%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y-32.05%
ROICexcg growth 5YN/A
ROICexc growth 3Y-33.38%
ROICexc growth 5YN/A
OM growth 3Y-13.56%
OM growth 5Y-5.58%
PM growth 3Y-59.09%
PM growth 5Y-39.26%
GM growth 3Y2.76%
GM growth 5Y3.16%
F-Score6
Asset Turnover1.9
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 4.35 | ||
| Debt/EBITDA | 2.98 | ||
| Cap/Depr | 184.76% | ||
| Cap/Sales | 3.45% | ||
| Interest Coverage | 3.69 | ||
| Cash Conversion | 106.02% | ||
| Profit Quality | 110.56% | ||
| Current Ratio | 0.98 | ||
| Quick Ratio | 0.74 | ||
| Altman-Z | 2.46 |
F-Score6
WACC9.78%
ROIC/WACC5.27
Cap/Depr(3y)122.96%
Cap/Depr(5y)152.59%
Cap/Sales(3y)2.04%
Cap/Sales(5y)2.01%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)366.67%
EPS 3Y-71.33%
EPS 5Y-48.53%
EPS Q2Q%220%
EPS Next Y166.59%
EPS Next 2Y40.1%
EPS Next 3Y24.88%
EPS Next 5Y42.78%
Revenue 1Y (TTM)-14.94%
Revenue growth 3Y12.26%
Revenue growth 5Y12.38%
Sales Q2Q%-0.62%
Revenue Next Year-2.93%
Revenue Next 2Y0.89%
Revenue Next 3Y2.93%
Revenue Next 5Y6.82%
EBIT growth 1Y-11.91%
EBIT growth 3Y-2.97%
EBIT growth 5Y6.11%
EBIT Next Year53.39%
EBIT Next 3Y25.44%
EBIT Next 5Y14.88%
FCF growth 1Y14.31%
FCF growth 3Y8.58%
FCF growth 5Y10.09%
OCF growth 1Y28.77%
OCF growth 3Y10.29%
OCF growth 5Y12.28%